You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLisdexamfetamine
Accession NumberDB01255
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin.
Structure
Thumb
Synonyms
Lisdexamfetamine
lisdexamfetamine dimesylate
NRP104
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vyvansecapsule30 mg/1oralShire LLC2007-02-23Not applicableUs
Vyvansecapsule20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-10Not applicableUs
Vyvansecapsule20 mgoralShire Pharma Canada Ulc2010-04-13Not applicableCanada
Vyvansecapsule70 mg/1oralShire LLC2007-02-23Not applicableUs
Vyvansecapsule10 mg/1oralAvera Mc Kennan Hospital2015-03-26Not applicableUs
Vyvansecapsule40 mg/1oralPhysicians Total Care, Inc.2009-03-20Not applicableUs
Vyvansecapsule40 mg/1oralShire LLC2007-12-10Not applicableUs
Vyvansecapsule40 mgoralShire Pharma Canada Ulc2010-04-14Not applicableCanada
Vyvansecapsule70 mg/1oralPhysicians Total Care, Inc.2010-03-04Not applicableUs
Vyvansecapsule70 mg/1oralAvera Mc Kennan Hospital2015-09-30Not applicableUs
Vyvansecapsule10 mg/1oralShire LLC2014-08-30Not applicableUs
Vyvansecapsule50 mg/1oralShire LLC2007-02-23Not applicableUs
Vyvansecapsule60 mgoralShire Pharma Canada Ulc2010-04-14Not applicableCanada
Vyvansecapsule50 mg/1oralPhysicians Total Care, Inc.2008-07-11Not applicableUs
Vyvansecapsule30 mgoralShire Pharma Canada Ulc2009-08-04Not applicableCanada
Vyvansecapsule20 mg/1oralShire LLC2007-12-10Not applicableUs
Vyvansecapsule60 mg/1oralShire LLC2007-12-10Not applicableUs
Vyvansecapsule10 mgoralShire Pharma Canada Ulc2015-06-26Not applicableCanada
Vyvansecapsule30 mg/1oralPhysicians Total Care, Inc.2008-07-11Not applicableUs
Vyvansecapsule50 mgoralShire Pharma Canada Ulc2009-08-04Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIH645GUL8KJ
CAS number608137-32-2
WeightAverage: 263.3785
Monoisotopic: 263.199762437
Chemical FormulaC15H25N3O
InChI KeyInChIKey=VOBHXZCDAVEXEY-JSGCOSHPSA-N
InChI
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
IUPAC Name
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
SMILES
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • Amphetamine or derivatives
  • Phenylpropane
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric populations aged 6 to 12 years.
PharmacodynamicsLisdexamfetamine is a pro-drug of dextroamphetamine. It works primarily by inducing the release of the neurotransmitters dopamine and norepinephrine from their storage areas in nerve terminals. Both of these transmitters contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation.
Mechanism of actionLisdexamfetamine is a pro-drug of dextroamphetamine. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Norepinephrine and dopamine contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation. However, the exact therapeutic action in ADHD is not known.
Related Articles
AbsorptionAfter oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Lisdexamfetamine is converted to dextroamphetamine and L-lysine, which is believed to occur by first-pass intestinal and/or hepatic metabolism. Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.

Route of eliminationNot Available
Half lifeThe plasma elimination half-life of lisdexamfetamine typically averaged less than one hour.
ClearanceNot Available
ToxicityManifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9858
Blood Brain Barrier+0.9444
Caco-2 permeable+0.664
P-glycoprotein substrateSubstrate0.6919
P-glycoprotein inhibitor INon-inhibitor0.9264
P-glycoprotein inhibitor IINon-inhibitor0.9802
Renal organic cation transporterNon-inhibitor0.8398
CYP450 2C9 substrateNon-substrate0.8303
CYP450 2D6 substrateNon-substrate0.621
CYP450 3A4 substrateNon-substrate0.7228
CYP450 1A2 substrateNon-inhibitor0.7025
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.7568
CYP450 3A4 inhibitorNon-inhibitor0.5499
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8494
Ames testNon AMES toxic0.7156
CarcinogenicityNon-carcinogens0.854
BiodegradationNot ready biodegradable0.8575
Rat acute toxicity2.0058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9688
hERG inhibition (predictor II)Non-inhibitor0.9004
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg/1
Capsuleoral10 mg
Capsuleoral20 mg/1
Capsuleoral20 mg
Capsuleoral30 mg
Capsuleoral30 mg/1
Capsuleoral40 mg
Capsuleoral40 mg/1
Capsuleoral50 mg/1
Capsuleoral50 mg
Capsuleoral60 mg/1
Capsuleoral60 mg
Capsuleoral70 mg/1
Prices
Unit descriptionCostUnit
Vyvanse 30 mg capsule6.24USD capsule
Vyvanse 50 mg capsule6.02USD capsule
Vyvanse 70 mg capsule5.85USD capsule
Vyvanse 40 mg capsule5.8USD capsule
Vyvanse 20 mg capsule5.26USD capsule
Vyvanse 60 mg capsule5.02USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7105486 No2003-02-242023-02-24Us
US7223735 No2003-02-242023-02-24Us
US7655630 No2003-02-242023-02-24Us
US7659253 No2003-02-242023-02-24Us
US7659254 No2003-02-242023-02-24Us
US7662787 No2003-02-242023-02-24Us
US7662788 No2003-02-242023-02-24Us
US7671030 No2003-02-242023-02-24Us
US7671031 No2003-02-242023-02-24Us
US7674774 No2003-02-242023-02-24Us
US7678770 No2003-02-242023-02-24Us
US7678771 No2003-02-242023-02-24Us
US7687466 No2003-02-242023-02-24Us
US7687467 No2003-02-242023-02-24Us
US7700561 No2003-02-242023-02-24Us
US7713936 No2003-02-242023-02-24Us
US7718619 No2003-02-242023-02-24Us
US7723305 No2003-02-242023-02-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility792 mg/mL (dimesylate salt)Not Available
logP1.06Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0877 mg/mLALOGPS
logP1.01ALOGPS
logP1.14ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.89ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area81.14 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.31 m3·mol-1ChemAxon
Polarizability31.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher, “Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof.” U.S. Patent US20120157706, issued June 21, 2012.

US20120157706
General References
  1. Jasinski DR, Krishnan S: Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009 Jun;23(4):410-8. doi: 10.1177/0269881108093841. Epub 2008 Jul 17. [PubMed:18635707 ]
  2. Madaan V: Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc). 2008 May;44(5):319-24. doi: 10.1358/dot.2008.44.5.1215724. [PubMed:18548134 ]
  3. Krishnan S, Moncrief S: An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):180-4. Epub 2006 Oct 11. [PubMed:17035599 ]
External Links
ATC CodesN06BA12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Lisdexamfetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of Lisdexamfetamine.
AceprometazineAceprometazine may decrease the stimulatory activities of Lisdexamfetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Lisdexamfetamine.
AcrivastineLisdexamfetamine may decrease the sedative activities of Acrivastine.
AlcaftadineLisdexamfetamine may decrease the sedative activities of Alcaftadine.
AlfentanilLisdexamfetamine may increase the analgesic activities of Alfentanil.
AlimemazineLisdexamfetamine may decrease the sedative activities of Alimemazine.
AlphacetylmethadolLisdexamfetamine may increase the analgesic activities of Alphacetylmethadol.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmineptineAmineptine may increase the stimulatory activities of Lisdexamfetamine.
AmisulprideAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Lisdexamfetamine.
Ammonium chlorideThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Ammonium chloride.
AmperozideAmperozide may decrease the stimulatory activities of Lisdexamfetamine.
AntazolineLisdexamfetamine may decrease the sedative activities of Antazoline.
AripiprazoleAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.
AsenapineAsenapine may decrease the stimulatory activities of Lisdexamfetamine.
AstemizoleLisdexamfetamine may decrease the sedative activities of Astemizole.
AzaperoneAzaperone may decrease the stimulatory activities of Lisdexamfetamine.
AzatadineLisdexamfetamine may decrease the sedative activities of Azatadine.
AzelastineLisdexamfetamine may decrease the sedative activities of Azelastine.
BenmoxinBenmoxin may increase the hypertensive activities of Lisdexamfetamine.
BezitramideLisdexamfetamine may increase the analgesic activities of Bezitramide.
BifeprunoxBifeprunox may decrease the stimulatory activities of Lisdexamfetamine.
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Lisdexamfetamine.
BrompheniramineLisdexamfetamine may decrease the sedative activities of Brompheniramine.
BuclizineLisdexamfetamine may decrease the sedative activities of Buclizine.
BuprenorphineLisdexamfetamine may increase the analgesic activities of Buprenorphine.
Butanoic AcidLisdexamfetamine may decrease the sedative activities of Butanoic Acid.
ButorphanolLisdexamfetamine may increase the analgesic activities of Butorphanol.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
CarbinoxamineLisdexamfetamine may decrease the sedative activities of Carbinoxamine.
CarfentanilLisdexamfetamine may increase the analgesic activities of Carfentanil.
CariprazineCariprazine may decrease the stimulatory activities of Lisdexamfetamine.
CaroxazoneCaroxazone may increase the hypertensive activities of Lisdexamfetamine.
CetirizineLisdexamfetamine may decrease the sedative activities of Cetirizine.
ChloropyramineLisdexamfetamine may decrease the sedative activities of Chloropyramine.
ChlorphenamineLisdexamfetamine may decrease the sedative activities of Chlorphenamine.
ChlorphenoxamineLisdexamfetamine may decrease the sedative activities of Chlorphenoxamine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Lisdexamfetamine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.
CimetidineLisdexamfetamine may decrease the sedative activities of Cimetidine.
CinnarizineLisdexamfetamine may decrease the sedative activities of Cinnarizine.
ClemastineLisdexamfetamine may decrease the sedative activities of Clemastine.
ClomipramineClomipramine may increase the stimulatory activities of Lisdexamfetamine.
ClozapineClozapine may decrease the stimulatory activities of Lisdexamfetamine.
CodeineLisdexamfetamine may increase the analgesic activities of Codeine.
CyamemazineCyamemazine may decrease the stimulatory activities of Lisdexamfetamine.
CyclizineLisdexamfetamine may decrease the sedative activities of Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.
CyproheptadineLisdexamfetamine may decrease the sedative activities of Cyproheptadine.
DapiprazoleDapiprazole may decrease the stimulatory activities of Lisdexamfetamine.
DesipramineDesipramine may increase the stimulatory activities of Lisdexamfetamine.
DesloratadineLisdexamfetamine may decrease the sedative activities of Desloratadine.
DexbrompheniramineLisdexamfetamine may decrease the sedative activities of Dexbrompheniramine.
Dexchlorpheniramine maleateLisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
DextromoramideLisdexamfetamine may increase the analgesic activities of Dextromoramide.
DextropropoxypheneLisdexamfetamine may increase the analgesic activities of Dextropropoxyphene.
DezocineLisdexamfetamine may increase the analgesic activities of Dezocine.
DiclofenamideDiclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
DihydrocodeineLisdexamfetamine may increase the analgesic activities of Dihydrocodeine.
DihydroetorphineLisdexamfetamine may increase the analgesic activities of Dihydroetorphine.
DihydromorphineLisdexamfetamine may increase the analgesic activities of Dihydromorphine.
DimenhydrinateLisdexamfetamine may decrease the sedative activities of Dimenhydrinate.
DimetindeneLisdexamfetamine may decrease the sedative activities of Dimetindene.
DimetotiazineLisdexamfetamine may decrease the sedative activities of Dimetotiazine.
DiphenhydramineLisdexamfetamine may decrease the sedative activities of Diphenhydramine.
DiphenoxylateLisdexamfetamine may increase the analgesic activities of Diphenoxylate.
DosulepinDosulepin may increase the stimulatory activities of Lisdexamfetamine.
DoxepinLisdexamfetamine may decrease the sedative activities of Doxepin.
DoxepinDoxepin may increase the stimulatory activities of Lisdexamfetamine.
DoxylamineLisdexamfetamine may decrease the sedative activities of Doxylamine.
DPDPELisdexamfetamine may increase the analgesic activities of DPDPE.
DroperidolDroperidol may decrease the stimulatory activities of Lisdexamfetamine.
EmedastineLisdexamfetamine may decrease the sedative activities of Emedastine.
EpinastineLisdexamfetamine may decrease the sedative activities of Epinastine.
EsmirtazapineLisdexamfetamine may decrease the sedative activities of Esmirtazapine.
EsmirtazapineEsmirtazapine may increase the stimulatory activities of Lisdexamfetamine.
EthopropazineLisdexamfetamine may decrease the sedative activities of Ethopropazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Lisdexamfetamine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
EthylmorphineLisdexamfetamine may increase the analgesic activities of Ethylmorphine.
EtorphineLisdexamfetamine may increase the analgesic activities of Etorphine.
FamotidineLisdexamfetamine may decrease the sedative activities of Famotidine.
FencamfamineFencamfamine may decrease the stimulatory activities of Lisdexamfetamine.
FentanylLisdexamfetamine may increase the analgesic activities of Fentanyl.
FexofenadineLisdexamfetamine may decrease the sedative activities of Fexofenadine.
FlunarizineLisdexamfetamine may decrease the sedative activities of Flunarizine.
FlupentixolFlupentixol may decrease the stimulatory activities of Lisdexamfetamine.
FluphenazineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.
FluspirileneFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.
FurazolidoneFurazolidone may increase the hypertensive activities of Lisdexamfetamine.
GuanethidineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Guanethidine.
HaloperidolHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.
HeroinLisdexamfetamine may increase the analgesic activities of Heroin.
HexamethylenetetramineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Hexamethylenetetramine.
HydracarbazineHydracarbazine may increase the hypertensive activities of Lisdexamfetamine.
HydrocodoneLisdexamfetamine may increase the analgesic activities of Hydrocodone.
HydromorphoneLisdexamfetamine may increase the analgesic activities of Hydromorphone.
HydroxyzineLisdexamfetamine may decrease the sedative activities of Hydroxyzine.
IloperidoneIloperidone may decrease the stimulatory activities of Lisdexamfetamine.
ImipramineImipramine may increase the stimulatory activities of Lisdexamfetamine.
Ioflupane I-123Lisdexamfetamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the hypertensive activities of Lisdexamfetamine.
IproniazidIproniazid may increase the hypertensive activities of Lisdexamfetamine.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Lisdexamfetamine.
IsothipendylLisdexamfetamine may decrease the sedative activities of Isothipendyl.
KetobemidoneLisdexamfetamine may increase the analgesic activities of Ketobemidone.
KetotifenLisdexamfetamine may decrease the sedative activities of Ketotifen.
L-Glutamic AcidThe serum concentration of Lisdexamfetamine can be decreased when it is combined with L-Glutamic Acid.
LevocabastineLisdexamfetamine may decrease the sedative activities of Levocabastine.
LevocetirizineLisdexamfetamine may decrease the sedative activities of Levocetirizine.
Levomethadyl AcetateLisdexamfetamine may increase the analgesic activities of Levomethadyl Acetate.
LevorphanolLisdexamfetamine may increase the analgesic activities of Levorphanol.
LithiumLithium may decrease the stimulatory activities of Lisdexamfetamine.
LodoxamideLisdexamfetamine may decrease the sedative activities of Lodoxamide.
LofentanilLisdexamfetamine may increase the analgesic activities of Lofentanil.
LoratadineLisdexamfetamine may decrease the sedative activities of Loratadine.
LoxapineLoxapine may decrease the stimulatory activities of Lisdexamfetamine.
LurasidoneLurasidone may decrease the stimulatory activities of Lisdexamfetamine.
MagaldrateMagaldrate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
MebanazineMebanazine may increase the hypertensive activities of Lisdexamfetamine.
MeclizineLisdexamfetamine may decrease the sedative activities of Meclizine.
MelperoneMelperone may decrease the stimulatory activities of Lisdexamfetamine.
MepyramineLisdexamfetamine may decrease the sedative activities of Mepyramine.
MequitazineLisdexamfetamine may decrease the sedative activities of Mequitazine.
MesoridazineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.
MethadoneLisdexamfetamine may increase the analgesic activities of Methadone.
Methadyl AcetateLisdexamfetamine may increase the analgesic activities of Methadyl Acetate.
MethapyrileneLisdexamfetamine may decrease the sedative activities of Methapyrilene.
MethazolamideMethazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Lisdexamfetamine.
Methylene blueMethylene blue may increase the hypertensive activities of Lisdexamfetamine.
MetiamideLisdexamfetamine may decrease the sedative activities of Metiamide.
MianserinLisdexamfetamine may decrease the sedative activities of Mianserin.
MinaprineMinaprine may increase the hypertensive activities of Lisdexamfetamine.
MirtazapineLisdexamfetamine may decrease the sedative activities of Mirtazapine.
MirtazapineMirtazapine may increase the stimulatory activities of Lisdexamfetamine.
MoclobemideMoclobemide may increase the hypertensive activities of Lisdexamfetamine.
MolindoneMolindone may decrease the stimulatory activities of Lisdexamfetamine.
MorphineLisdexamfetamine may increase the analgesic activities of Morphine.
NalbuphineLisdexamfetamine may increase the analgesic activities of Nalbuphine.
NialamideNialamide may increase the hypertensive activities of Lisdexamfetamine.
NizatidineLisdexamfetamine may decrease the sedative activities of Nizatidine.
NormethadoneLisdexamfetamine may increase the analgesic activities of Normethadone.
NortriptylineNortriptyline may increase the stimulatory activities of Lisdexamfetamine.
OctamoxinOctamoxin may increase the hypertensive activities of Lisdexamfetamine.
OlanzapineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.
OlopatadineLisdexamfetamine may decrease the sedative activities of Olopatadine.
OndansetronOndansetron may decrease the stimulatory activities of Lisdexamfetamine.
OpiumLisdexamfetamine may increase the analgesic activities of Opium.
OsanetantOsanetant may decrease the stimulatory activities of Lisdexamfetamine.
OxycodoneLisdexamfetamine may increase the analgesic activities of Oxycodone.
OxymorphoneLisdexamfetamine may increase the analgesic activities of Oxymorphone.
PaliperidonePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.
PargylinePargyline may increase the hypertensive activities of Lisdexamfetamine.
PemirolastLisdexamfetamine may decrease the sedative activities of Pemirolast.
PentazocineLisdexamfetamine may increase the analgesic activities of Pentazocine.
PerospironePerospirone may decrease the stimulatory activities of Lisdexamfetamine.
PerphenazinePerphenazine may decrease the stimulatory activities of Lisdexamfetamine.
PethidineLisdexamfetamine may increase the analgesic activities of Pethidine.
PhenelzinePhenelzine may increase the hypertensive activities of Lisdexamfetamine.
PhenindamineLisdexamfetamine may decrease the sedative activities of Phenindamine.
PheniprazinePheniprazine may increase the hypertensive activities of Lisdexamfetamine.
PheniramineLisdexamfetamine may decrease the sedative activities of Pheniramine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Lisdexamfetamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Lisdexamfetamine.
PimozidePimozide may decrease the stimulatory activities of Lisdexamfetamine.
PipamperonePipamperone may decrease the stimulatory activities of Lisdexamfetamine.
PipotiazinePipotiazine may decrease the stimulatory activities of Lisdexamfetamine.
PirlindolePirlindole may increase the hypertensive activities of Lisdexamfetamine.
PivhydrazinePivhydrazine may increase the hypertensive activities of Lisdexamfetamine.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
PromazinePromazine may decrease the stimulatory activities of Lisdexamfetamine.
PromethazineLisdexamfetamine may decrease the sedative activities of Promethazine.
PropericiazinePropericiazine may decrease the stimulatory activities of Lisdexamfetamine.
ProtriptylineProtriptyline may increase the stimulatory activities of Lisdexamfetamine.
QuetiapineQuetiapine may decrease the stimulatory activities of Lisdexamfetamine.
RanitidineLisdexamfetamine may decrease the sedative activities of Ranitidine.
RasagilineRasagiline may increase the hypertensive activities of Lisdexamfetamine.
RemifentanilLisdexamfetamine may increase the analgesic activities of Remifentanil.
RemoxiprideRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.
ReserpineReserpine may decrease the stimulatory activities of Lisdexamfetamine.
RisperidoneRisperidone may decrease the stimulatory activities of Lisdexamfetamine.
Roxatidine acetateLisdexamfetamine may decrease the sedative activities of Roxatidine acetate.
SafrazineSafrazine may increase the hypertensive activities of Lisdexamfetamine.
SelegilineSelegiline may increase the hypertensive activities of Lisdexamfetamine.
SertindoleSertindole may decrease the stimulatory activities of Lisdexamfetamine.
Spaglumic AcidLisdexamfetamine may decrease the sedative activities of Spaglumic Acid.
SufentanilLisdexamfetamine may increase the analgesic activities of Sufentanil.
SulpirideSulpiride may decrease the stimulatory activities of Lisdexamfetamine.
TapentadolLisdexamfetamine may increase the analgesic activities of Tapentadol.
TerfenadineLisdexamfetamine may decrease the sedative activities of Terfenadine.
TesmilifeneLisdexamfetamine may decrease the sedative activities of Tesmilifene.
ThioproperazineThioproperazine may decrease the stimulatory activities of Lisdexamfetamine.
ThioridazineThioridazine may decrease the stimulatory activities of Lisdexamfetamine.
ThiothixeneThiothixene may decrease the stimulatory activities of Lisdexamfetamine.
ThonzylamineLisdexamfetamine may decrease the sedative activities of Thonzylamine.
TianeptineTianeptine may increase the stimulatory activities of Lisdexamfetamine.
ToloxatoneToloxatone may increase the hypertensive activities of Lisdexamfetamine.
TramadolLisdexamfetamine may increase the analgesic activities of Tramadol.
TranilastLisdexamfetamine may decrease the sedative activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Lisdexamfetamine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Lisdexamfetamine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.
TrimipramineTrimipramine may increase the stimulatory activities of Lisdexamfetamine.
TripelennamineLisdexamfetamine may decrease the sedative activities of Tripelennamine.
TriprolidineLisdexamfetamine may decrease the sedative activities of Triprolidine.
Vitamin CThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Lisdexamfetamine.
ZotepineZotepine may decrease the stimulatory activities of Lisdexamfetamine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Lisdexamfetamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Hamidovic A, Dlugos A, Palmer AA, de Wit H: Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010 Mar;40(2):255-61. doi: 10.1007/s10519-009-9331-7. Epub 2010 Jan 21. [PubMed:20091113 ]
Comments
comments powered by Disqus
Drug created on May 14, 2007 19:24 / Updated on September 28, 2016 02:25